Effect of Oral Resveratrol-Loaded Nanoliposomes on Hyperlipidemia Via Toll-Like Receptor 3 and Tir Domain-Containing Adaptor Inducing Interferon-Β Protein Expression in an Animal Model Publisher

Summary: Can nanoliposomes lower cholesterol? Study finds RES-loaded nanoliposomes reduce TC & LDL-C in HFD rats. #Hyperlipidemia #Nanoliposomes

Beheshtkhoo N¹ ; Jadidi Kouhbanani MA¹ ; Daghighi SM² ; Shakouri Nikjeh M² ; Esmaeili Z¹ ; Khosravani M¹ ; Adabi M^{1, 3}
Source: Journal of Liposome Research Published:2025

Abstract

Hyperlipidemia, a critical risk factor for various health conditions, necessitates innovative therapeutic strategies. Investigating the effectiveness of liposomal formulations in managing hyperlipidemia is essential. Resveratrol (RES)-loaded nanoliposomes present a promising new approach for hyperlipidemia treatment. In this study, we investigated the anti-hyperlipidemic potential of RES-loaded nanoliposomes in high-fat diet (HFD)-fed rats. The nanoliposomes were prepared using a thin-film hydration method. According to transmission electron microscopy (TEM) and dynamic light scattering (DLS) results, the mean size of prepared RES-loaded nanoliposomes were about 42 nm and 68 nm, respectively, with a zeta potential of −65.6 mV. The entrapment efficiency and loading content were 83.78% and 14.25%, respectively. Additionally, the RES-loaded nanoliposomes exhibited controlled release kinetics compared to the free RES form. Moreover, in a hyperlipidemic rat model induced by an HFD, orally administered RES-loaded nanoliposomes significantly reduced total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and triglycerides (TG), while concurrently increasing high-density lipoprotein cholesterol (HDL-C) levels. Additionally, liver damage induced by HFD was alleviated by RES-loaded nanoliposomes. The expression levels of Toll-like receptor 3 (TLR3) and TIR domain-containing adaptor-inducing interferon-β (TRIF) were assessed using fluorescence immunohistochemistry. Notably, RES-loaded nanoliposomes significantly reduced the expression of these protein. The effect of RES-loaded nanoliposomes was measured on body weight of HFD rats, demonstrting RES-loaded nanoliposomes hold promise for weight management. These findings underscore the potential of RES-loaded nanoliposomes as a safe and effective therapeutic option for hyperlipidemia. © 2025 Informa UK Limited, trading as Taylor & Francis Group.